Partial win for Mylan as Fed Circuit cancels Boehringer patents

17-03-2020

Rory O'Neill

Partial win for Mylan as Fed Circuit cancels Boehringer patents

ricochet64 / Shutterstock.com

The US Court of Appeals for the Federal Circuit has rescued one Boehringer Ingelheim patent, covering a type 2 diabetes treatment, from invalidation but affirmed a New Jersey district court’s cancellation of two others.


Mylan, Federal Circuit, Boehringer Ingelheim, type 2 diabetes, DPP-IV inhibitor, US District Court for the District of New Jersey, patent invalidation

LSIPR